Has this been posted? From a friend of MSB...
Re" Cleveland Clinic Crohn's trial...
Anyway, results very good in the P1B/2A trial. Of the 23 patients, 18 received the MSCs and 5 were controls. No adverse events from the MSC treatment.
83% of the treatment group had complete clinical and radiographic healing (15/18 patients) versus only 40% of the controls (2/5 patients).
Disease activity index, incontinence and vanassche scores all significantly decreased in treatment patients at 6 months vs none decreased in the control group.
Conclusion: Bone marrow-derived MSCs offer a safe and effective alternative treatment approach for severe peri*&^% fistulizing Crohn's disease.
Early days, and a couple of P3 trials are yet to be done, but this could be another potential source of a strategic partnership .
Cell Therapy News/Articles, page-17290
-
- There are more pages in this discussion • 531 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |